Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Francis

Internal Medicine South Williamson, KY Medical Doctor

NPI 1780663971 CMS profile 171810

306 Hospital Dr, Ste 202C, South Williamson, KY 41503

Open in the dashboard

General payments

$9,757

624 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Francis of South Williamson, KY is reported in the CMS Open Payments database as having received $9,757 across 624 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $814 45
2024 General $1,011 58
2023 General $1,081 63
2022 General $1,662 108
2021 General $1,971 135
2020 General $1,160 86
2019 General $2,057 129

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Francis
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Brian Francis were reported at $814. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Brian Francis Internal Medicine median Middle half National median
2019 $2,057 $159 $48–$570 $163
2020 $1,160 $119 $33–$402 $114
2021 $1,971 $135 $37–$521 $132
2022 $1,662 $141 $42–$496 $149
2023 $1,081 $149 $45–$519 $160
2024 $1,011 $154 $47–$537 $164
2025 $814 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,209 85 payments
  2. Janssen Pharmaceuticals, Inc $1,125 45 payments
  3. AstraZeneca Pharmaceuticals LP $927 46 payments
  4. AbbVie, Inc. $774 53 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $619 40 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $475 38 payments
  7. Lilly USA, LLC $460 38 payments
  8. Sanofi-Aventis U.S. LLC $430 33 payments
  9. Amgen Inc. $412 26 payments
  10. Abbott Laboratories $381 22 payments
  11. Other $2,947 198 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,738 621 payments
  2. Education $19 3 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,126 79 payments
  2. XARELTO $1,007 42 payments
  3. RYBELSUS $870 61 payments
  4. FARXIGA $663 28 payments
  5. XIFAXAN $619 40 payments
  6. BREZTRI $479 17 payments
  7. UBRELVY $449 28 payments
  8. FreeStyle Libre 2 $381 22 payments
  9. GEMTESA $335 22 payments
  10. Kerendia $303 20 payments
  11. Other $6,304 442 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 249 drugs

Part D claims

25,261

Median for Family Practice: 1,826

Drug cost

$1,946,842

Median for Family Practice: $120,094

Branded share of claims

26.2%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 167 $218,930
Ozempic Semaglutide Brand 180 $186,477
Jardiance Empagliflozin Brand 151 $152,468
Tradjenta Linagliptin Brand 137 $118,662
Eliquis Apixaban Brand 78 $88,081
Xarelto Rivaroxaban Brand 87 $76,025
Entresto Sacubitril/Valsartan Brand 43 $61,853
Farxiga Dapagliflozin Propanediol Brand 63 $60,297
Januvia Sitagliptin Phosphate Brand 50 $54,898
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 66 $51,660

The 10 drugs with the highest cost, of 249 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $145
$145 — —
UBRELVY
  • AbbVie, Inc. $109
$109 — —
Otezla
  • Amgen Inc. $57
$57 — —
Repatha
  • Amgen Inc. $57
$57 — —
RYBELSUS
  • Novo Nordisk Inc $57
$57 41 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

624 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record